Last reviewed · How we verify
Erispan (FLUDIAZEPAM)
Erispan (generic name: FLUDIAZEPAM) is a fludiazepam drug. It is currently in Phase 2 development.
Fludiazepam works by enhancing the calming effect of a neurotransmitter called GABA in the brain.
Fludiazepam, also known as Erispan, is a small molecule belonging to the drug class of benzodiazepines. Its mechanism of action involves modulating the activity of neurotransmitters in the brain, specifically enhancing the effect of gamma-aminobutyric acid (GABA), which has a calming effect on the nervous system. However, due to the lack of available information, its target, FDA approval status, and commercial status are unknown. As a result, its approved indications, half-life, bioavailability, and generic manufacturers are also unclear. Further research is necessary to determine the full scope of its use and safety considerations.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
CNS / neurology attrition
-3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | FLUDIAZEPAM |
|---|---|
| Drug class | fludiazepam |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | Phase 2 |
Mechanism of action
Imagine your brain is like a busy city with many people talking at once. GABA is like a traffic cop that helps calm everyone down and keep the city running smoothly. Fludiazepam helps the traffic cop do its job more effectively, which can lead to a sense of relaxation and reduced anxiety.
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Erispan CI brief — competitive landscape report
- Erispan updates RSS · CI watch RSS
Frequently asked questions about Erispan
What is Erispan?
How does Erispan work?
What is the generic name of Erispan?
What drug class is Erispan in?
What development phase is Erispan in?
Related
- Drug class: All fludiazepam drugs
- Therapeutic area: All drugs in Neuroscience
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing